BioLife Solutions Inc (NASDAQ:BLFS) was the target of a significant drop in short interest during the month of December. As of December 31st, there was short interest totalling 1,620,000 shares, a drop of 5.8% from the December 15th total of 1,720,000 shares. Based on an average daily volume of 144,600 shares, the short-interest ratio is currently 11.2 days. Approximately 10.7% of the shares of the company are sold short.

Shares of BLFS stock traded down $0.17 on Thursday, reaching $15.81. The company’s stock had a trading volume of 4,022 shares, compared to its average volume of 110,725. The stock’s fifty day simple moving average is $16.13 and its 200-day simple moving average is $17.33. BioLife Solutions has a 1 year low of $11.60 and a 1 year high of $22.44. The company has a market capitalization of $325.16 million, a price-to-earnings ratio of 113.11, a price-to-earnings-growth ratio of 11.51 and a beta of 1.24. The company has a current ratio of 6.49, a quick ratio of 5.33 and a debt-to-equity ratio of 0.01.

BioLife Solutions (NASDAQ:BLFS) last released its quarterly earnings results on Tuesday, November 12th. The medical equipment provider reported $0.01 earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of $0.01. BioLife Solutions had a net margin of 46.77% and a return on equity of 5.37%. The company had revenue of $6.60 million for the quarter, compared to the consensus estimate of $7.65 million. Equities research analysts forecast that BioLife Solutions will post 0.05 earnings per share for the current year.

In other BioLife Solutions news, CEO Michael Rice sold 10,000 shares of the company’s stock in a transaction that occurred on Thursday, November 14th. The shares were sold at an average price of $13.98, for a total value of $139,800.00. Following the completion of the transaction, the chief executive officer now directly owns 185,014 shares in the company, valued at $2,586,495.72. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, VP James Mathers sold 2,500 shares of the company’s stock in a transaction that occurred on Tuesday, October 29th. The stock was sold at an average price of $17.31, for a total transaction of $43,275.00. Following the completion of the transaction, the vice president now owns 19,884 shares of the company’s stock, valued at $344,192.04. The disclosure for this sale can be found here. Insiders sold 102,247 shares of company stock worth $1,625,347 over the last three months. Insiders own 27.00% of the company’s stock.

Large investors have recently modified their holdings of the business. JPMorgan Chase & Co. purchased a new stake in BioLife Solutions in the 2nd quarter valued at about $30,000. Alpine Woods Capital Investors LLC increased its stake in shares of BioLife Solutions by 9.0% during the third quarter. Alpine Woods Capital Investors LLC now owns 10,900 shares of the medical equipment provider’s stock worth $181,000 after purchasing an additional 900 shares in the last quarter. Morgan Stanley raised its stake in BioLife Solutions by 17.5% in the 2nd quarter. Morgan Stanley now owns 11,506 shares of the medical equipment provider’s stock valued at $195,000 after purchasing an additional 1,713 shares during the last quarter. Charles Schwab Investment Management Inc. acquired a new position in BioLife Solutions in the 2nd quarter valued at $283,000. Finally, Price T Rowe Associates Inc. MD lifted its holdings in BioLife Solutions by 32.3% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 29,626 shares of the medical equipment provider’s stock valued at $502,000 after purchasing an additional 7,226 shares in the last quarter. 50.16% of the stock is owned by institutional investors and hedge funds.

Several research analysts recently weighed in on BLFS shares. Stephens started coverage on shares of BioLife Solutions in a report on Tuesday, January 7th. They issued an “overweight” rating and a $23.00 target price for the company. BidaskClub cut BioLife Solutions from a “buy” rating to a “hold” rating in a research report on Wednesday, December 11th. TheStreet upgraded shares of BioLife Solutions from a “c” rating to a “b-” rating in a research report on Friday, November 29th. Oppenheimer initiated coverage on shares of BioLife Solutions in a research note on Wednesday, November 20th. They set an “outperform” rating and a $22.00 target price for the company. Finally, Zacks Investment Research upgraded shares of BioLife Solutions from a “sell” rating to a “hold” rating in a report on Monday. Three analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $22.50.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets grade cell and tissue hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs in the United States. Its products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced cell damage and death.

Read More: The risks of owning bonds

Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.